Anxiety and Depression in Drug-Dependent Patients with Cluster C Personality Disorders

Carlos Roncero1,2,3, Adelia de Miguel4, Ascensión Fumero4, Alfonso C. Abad2,5, Rita Martín4, Juan Manuel Bethencourt4, Lara Grau-López2,3,5, Laia Rodríguez-Cintas2,3 and Constanza Daigre2,3,5

1 Psychiatric Service, University of Salamanca Health Care Complex, Institute of Biomedicine of Salamanca, University of Salamanca, Salamanca, Spain, 2 Addiction and Dual Diagnosis Unit, Hospital Universitari Vall d’Hebron-ASPB, Barcelona, Spain, 3 Psychiatry Department, Universitat Autònoma de Barcelona, Barcelona, Spain, 4 Sciences of Health School, Universidad de La Laguna, Tenerife, Spain, 5 Psychiatry Services, Hospital Universitario Vall d’Hebron, CIBERSAM, Barcelona, Spain

Objective: Comorbidity between personality disorders (PD) and substance-use disorders (SUD) is one of the most common findings in the psychiatric field. The patients with Cluster C disorders present maladjustment traits often characterized by high levels of anxiety. The main aim of this study was to find evidences about higher anxiety and depression prevalence on Cluster C than others Clusters, analyzing similarities and differences within, with other Cluster A and B PD patients and patients without PD.

Method: A total of 822 substance dependent patients (ages18–78; Mean = 38.35, SD = 10.14) completed the structured clinical interview for DSM-IV Axis I and Axis II disorders, Beck Depression Inventory, and State-Trait Anxiety Inventory.

Results: Results supported poly-consumption in Cluster C patients, being greater alcohol consumption as well as abuse of both stimulants and depressants. Anxiety and depression did not show just one pattern for all patients with SUD-Cluster C PD. There was a relation between anxiety and depression for all the groups except for the Dependent-PD.

Conclusion: Interventions should focus on aspects like depression and anxiety more than on the substance consumed.

Keywords: addiction, substance-use disorder, personality, cluster C, anxiety, depression

INTRODUCTION

Personality disorders (PDs) are behavioral patterns with rigid traits that remain stable over time. The individual's developmental stage or social–cultural environment should not be used as an explanation of impairments in personality functioning and the individual's personality trait expression as it is explained in DSM-5. They directly affect perceptions, the way of thinking and relating to the world, and the control of individual impulses (1). Comorbidity of Axis I disorders complicates both the diagnosis and prognosis of PD (2). One of the most common comorbidities of patients with PD involves substance-use disorders (SUDs), and, vice versa, maladjustment (3, 4) and PD are more frequent among addicts (5–7).
Between 65 and 90% of individuals with addictions have PD (8, 9). The most commonly detected PD are Limit and Antisocial Cluster B ones; followed by Avoidant, Passive-aggressive and Obsessive–Compulsive PDs from Cluster C; and finally Schizotypal PD from Cluster A (6, 10). However, there are discrepancies, and not all studies coincide with this ranking. These discrepancies could be explained by the type of substance being consumed; the assessment methods or techniques used; the time of the assessment; being outpatients or inpatients; poly-consumption (11, 12), or even the stability of the disorders (13).

DSM-IV criteria seem to be a valid tool for the diagnosis of PD. A previous study supported the validity of the DSM-IV criteria for Avoidant PD in Hispanic population with SUDs (14).

Personality disorders from Cluster C (or core anxiety) group together excessively nervous or fearful individuals, who are characterized by great emotional instability that is evidenced by personal passivity and suffering. This cluster consists of Avoidant, Dependent, and Obsessive–Compulsive PDs (1). Cluster C traits could be detected even in adolescent population (15). Adolescents with maladaptive personality traits are more at risk of developing cannabis dependence or other SUDs (16).

To explain the association between PD Cluster C and SUD, two hypotheses have been put forward. One is the self-medication hypothesis, which proposes that individuals discover that substances alleviate or change a series of painful affective states (17, 18). In the specific case of Cluster C, directly linked to anxiety, it is hypothesized that consumption of substances is aimed at counteracting feelings of isolation and a lack of social relations. Consequently, drugs can be used to substitute these relations or simply produce a feeling of tranquility in social situations. These characteristics indicate a tendency among patients in this group of disorders toward an overall greater drug consumption, including alcohol and other substances, both stimulants and depressants (19, 20).

The second hypothesis, known as stress response dampening, suggests that individuals with high scores in personality traits like stress reactivity, sensitivity to anxiety, and neuroticism are vulnerable to stressful events. These individuals tend to respond to stress with anxiety and mood swings, which can, in turn, push them toward substance consumption (2).

Beyond these hypotheses, previous studies have shown anatomico-functional correlates between Cluster C addicted patients and their willingness to change (21).

Furthermore, it has been suggested that patients with SUD who have PD usually show more psychopathological problems, mainly anxiety and depression (8, 22–25). Kranzler et al. (26) highlight that anxiety and depression are substantially higher among SUD patients with PDs than among those without. Additionally, Langás et al. point out that symptoms of depression and addiction are more serious in SUD patients with PD (8). Despite studies on the existence of psychiatric comorbidity between Cluster C and SUD (8, 20) and of the possible influence of anxiety and depression on PD, there have been no studies involving large samples on the influence of anxiety and depression on patients with Cluster C PD.

Therefore, the aim of this work is to determine the prevalence of Cluster C PD in patients with SUD who seek treatment, to analyze differences in clinical variables between the various disorder subtypes of Cluster C and evaluate if the variables of anxiety and depression differentiate these patients from those who do not present disorders of this cluster. We hypothesize that Cluster C disorders will be common in addicts, that there will be clinical and consumption differences among the different disorders of this cluster, and that anxiety and depression will be distinct in each disorder and will influence clinical variables differently.

Materials and Methods

Participants

This descriptive study involved a clinical sample of 822 substance dependent patients according to the DSM-IV-TR criteria (621 males and 201 females, mean age = 38.35, SD = 10.14, range 18–78). The study was conducted in the outpatient drug clinic of Vall d’Hebron Hospital’s Psychiatry Service of the (CAS Vall d’Hebron) in Barcelona, Spain.

Measures

Patients were visited by a psychiatrist, and three psychological evaluation visits were carried out by psychologists. The psychological evaluation visits were carried out in the first month of starting treatment in our Unit. Sociodemographic and clinical data were recorded using a questionnaire designed ad hoc, as well as evaluating all patients using the following instruments.

SCID I (The Structured Clinical Interview for DSM-IV Axis I disorders), a widely used scale that has shown good psychometric properties, was used to assess SUD (27).

SCID II (The Structured Clinical Interview for DSM-IV for Axis II) was used to assess PDs. This tool has shown adequate reliability and usefulness providing clear discrimination among Axis II disorders (28).

Beck Depression Inventory (BDI) (29, 30) is scored by summing the rating for all its 21 items to obtain a total score ranging from 0 to 63. Each symptom’s severity is rated on a 4-point scale (0–3).

State–Trait Anxiety Inventory (STAI) (31) is a 40-item measure that indicates the intensity of feelings of anxiety. It distinguishes between state anxiety (i.e., a temporary condition experienced in specific situations) and trait anxiety (i.e., a general tendency to perceive situations as threatening). Each scale consists of 20 items rated on a 4-point Likert scale. STAI has demonstrated good internal consistency, test–retest reliability in trait anxiety, sensitivity to detection of stress in state anxiety, and convergent and discriminant validity (32–35).

Procedure

Data were collected between January 2005 and June 2013. Inclusion criteria were patients were 18 years or older, presented substance dependence according to DSM-IV-TR, provided a signed consent form to participate in the study, and finished the assessment process. Exclusion criteria were: intoxication at baseline examination, severe somatic disease at baseline.
examination, and low language proficiency. The study protocol was approved by the hospital’s ethics committee (Comité Ético de Investigación Clínica Vall d’Hebron). Patients did not receive monetary compensation for their participation in the study. This study was part of a wider project on comorbidity on drug dependence.

Using IBM SPSS 19, cross-tabs with χ², differential analysis with Student’s t and Cohen’s d, and Pearson’s r were performed. To study poly-consumption, regardless of the main drug being treated, data were crossed on different substance use and the variable PD criteria. To facilitate calculations, each use/or abuse variable is dichotomized in such a way that no-use is scored with a 0 and the use-abuse-dependence is 1.

RESULTS

Demographics and Comorbidity PD-SUD
In the sample, 9.5% of patients fulfilled the criteria for at least one PD from Cluster C, with the most frequent diagnosis being Avoidant PD. In addition, 28.9% fulfilled PD criteria for Clusters A and B but not for C, and 61.6% did not fulfill the criteria for any PD (see Table 1).

Patients with a Cluster C disorder often had another PD: 14 Avoidant PD, 4 Dependent PD, and 5 Obsessive–Compulsive PD and also met the criteria for one or more PD from Clusters A and B (17.9, 5.12, and 6.4%, respectively within Cluster C). Finally, 5 (6.4%) participants showed two or three PD from Cluster C together with one or more PD from Clusters A and B.

It was found that 70.5% of patients with a Cluster C PD were men, although there were clear differences in the type of PD, Obsessive–Compulsive PD (85.7%) was the most common and to a significantly lesser degree Dependent PD (33.7%) (χ² = 12.19, p = 0.007).

The average age of patients was over 35 years old with statistically significant differences between the Without PD group and the group of patients from Clusters A and B (39.85 and 35.29, respectively, t = 6.28, p < 0.001). Within Cluster C, there were no differences in age (F = 0.339, p = 0.797).

A different pattern in PD prevalence was identified depending on the main substance consumed. Thus, Dependent PD was mainly present in patients who consumed benzodiazepines, and Obsessive–Compulsive PD were more common among those who consumed alcohol, opioids, cocaine, and cannabis.

Poly-Consumption of Drugs Regardless of Substance Use of Treatment
Table 2 shows the data for use/abuse of substances depending on their main effect on central nervous system (depressants, stimulants, and hallucinogens).

Alcohol, tobacco, cocaine, and cannabis were the drugs consumed by the majority of patients. However, patients without PD—compared to those with—showed greater alcohol consumption (χ² = 7.88, p = 0.02). Compared to patients with disorders from Cluster A and B, those with Cluster C disorders and those without PD consumed fewer opiates (χ² = 18.2, p = 0.000) and less methadone (χ² = 11.0, p = 0.004). There was a higher percentage
Table 2: Drug abuse of among drug-dependent patients.

|                          | Without personality disorder (n = 506) | Clusters A and B (n = 238) | Cluster C (n = 78) |
|--------------------------|---------------------------------------|----------------------------|-------------------|
|                          | n          | %          | n          | %          | n          | %          | χ²  | p    |
| Alcohol                  | 431        | 85.2       | 190        | 79.8       | 57         | 74.0       | 25  | 71.4 |
| Only alcohol             | 15         | 2.96       | –          | –          | 3          | 4.00       | 1   | 28.6 |
| Benztropine              | 159        | 31.4       | 102        | 42.9       | 30         | 39.0       | 13  | 37.1 |
| Only benzodiazepines     | 1          | 0.20       | –          | –          | 1          | 1.30       | 3   | 8.6  |
| Opioid                   | 119        | 23.5       | 91         | 38.2       | 18         | 23.4       | 10  | 28.6 |
| Methadone                | 103        | 20.4       | 78         | 32.8       | 15         | 20.0       | 8   | 27.4 |

**Depressant drugs**

|                          | Without personality disorder (n = 506) | Clusters A and B (n = 238) | Cluster C (n = 78) |
|--------------------------|---------------------------------------|----------------------------|-------------------|
|                          | n          | %          | n          | %          | n          | %          | χ²  | p    |
| Alcohol                  | 431        | 85.2       | 190        | 79.8       | 57         | 74.0       | 25  | 71.4 |
| Only alcohol             | 15         | 2.96       | –          | –          | 3          | 4.00       | 1   | 28.6 |
| Benzo diazepine          | 159        | 31.4       | 102        | 42.9       | 30         | 39.0       | 13  | 37.1 |
| Only benzo diazepines    | 1          | 0.20       | –          | –          | 1          | 1.30       | 3   | 8.6  |
| Opioid                   | 119        | 23.5       | 91         | 38.2       | 18         | 23.4       | 10  | 28.6 |
| Methadone                | 103        | 20.4       | 78         | 32.8       | 15         | 20.0       | 8   | 27.4 |

**Stimulant drugs**

|                          | Without personality disorder (n = 506) | Clusters A and B (n = 238) | Cluster C (n = 78) |
|--------------------------|---------------------------------------|----------------------------|-------------------|
|                          | n          | %          | n          | %          | n          | %          | χ²  | p    |
| Alcohol                  | 431        | 85.2       | 190        | 79.8       | 57         | 74.0       | 25  | 71.4 |
| Only alcohol             | 15         | 2.96       | –          | –          | 3          | 4.00       | 1   | 28.6 |
| Benzo diazepine          | 159        | 31.4       | 102        | 42.9       | 30         | 39.0       | 13  | 37.1 |
| Only benzo diazepines    | 1          | 0.20       | –          | –          | 1          | 1.30       | 3   | 8.6  |
| Opioid                   | 119        | 23.5       | 91         | 38.2       | 18         | 23.4       | 10  | 28.6 |
| Methadone                | 103        | 20.4       | 78         | 32.8       | 15         | 20.0       | 8   | 27.4 |

**Hallucinogenic drugs**

|                          | Without personality disorder (n = 506) | Clusters A and B (n = 238) | Cluster C (n = 78) |
|--------------------------|---------------------------------------|----------------------------|-------------------|
|                          | n          | %          | n          | %          | n          | %          | χ²  | p    |
| Alcohol                  | 431        | 85.2       | 190        | 79.8       | 57         | 74.0       | 25  | 71.4 |
| Only alcohol             | 15         | 2.96       | –          | –          | 3          | 4.00       | 1   | 28.6 |
| Benzo diazepine          | 159        | 31.4       | 102        | 42.9       | 30         | 39.0       | 13  | 37.1 |
| Only benzo diazepines    | 1          | 0.20       | –          | –          | 1          | 1.30       | 3   | 8.6  |
| Opioid                   | 119        | 23.5       | 91         | 38.2       | 18         | 23.4       | 10  | 28.6 |
| Methadone                | 103        | 20.4       | 78         | 32.8       | 15         | 20.0       | 8   | 27.4 |

Depressive Symptomatology and Anxiety

The levels of depressive and trait anxiety and state anxiety were studied as a function of Axis II (Figure 1). Significant differences appeared among different clusters (p < 0.001). Depressive symptomatology measured by BDI was similar for Avoidant PD and Dependent PD, whereas the clusters C showed lower depressive symptoms compared to the other two PDs (p < 0.001). In the case of stimulants, patients with Cluster C PD typically showed lower tobacco consumption compared to the other two PDs (p < 0.0001), whereas cocaine was used by patients with Cluster C PD more frequently compared to the other two PDs (p < 0.0001). Finally, regarding drugs with hallucinogenic effects, there were no differences among amphetamines use between clusters.
(Cohen's $d$ close to 0), whereas the Obsessive–Compulsive PD scored higher (large Cohen's $d$).

Additionally, regarding anxiety there were clear differences within Cluster C. Dependent PD scored higher than Avoidant and Obsessive–Compulsive PD (Cohen's $d$ moderate and large in both comparisons). Those with Avoidant PD scored higher than Obsessive–Compulsive, although the difference was more moderate.

Furthermore, depressive symptomatology and anxiety were significantly positively correlated (Table 4). However, when PD types within Cluster C were analyzed, anxiety was not related to the depressive symptomatology in Dependent PD ($r = -0.05$ and $r = 0.10$ for trait and state anxiety, respectively).

Regardless of having a PD or not, there was a close relationship between depression and anxiety, but it was found that within Cluster C, patients with Dependent PD were different to the rest as their responses did not indicate any relation between depression and anxiety.

### Depressive Symptomatology and Anxiety in Relation to Treatment Indicators

To analyze the relevance of depressive symptomatology and anxiety with objective indicators of treatment, the corresponding correlations between depression, trait anxiety, and state anxiety scales were calculated for three treatment indicators: number of detoxifications, number of admissions and number of treatments in health centers.

In participants Without PD and in participants with Cluster A and B PD, the range of $r$ was $-0.7$ and $0.13$, indicating the absence of a relation between psychological factors and treatment indicators. However, for Cluster C, though the general scenario is similar to the one above, correlations of $0.24$ appear between the two scales of anxiety and depression. Carrying out a zonal analysis within this cluster (Table 5), in the case of Avoidant PD and Obsessive–Compulsive PD, the correlation pattern approaches 0. However, in Dependent PD, there are high negative correlations between depressive symptomatology and treatment indicators, whereas there are moderately positive ones between trait and state anxiety and the indicators, except for the number of detoxifications. When cases of comorbidity within Cluster C were analyzed, the scenario was different: state anxiety was lower, the greater the number of detoxifications and treatments, whereas the number of admissions increased with greater depressive symptomatology and greater trait anxiety.
DISCUSSION

Almost 40% of the patients studied have a PD and nearly 10% have a PD from Cluster C. The findings obtained in seeking treatment patients attended at outpatient clinical units is consistent with other studies with smaller samples (8, 9, 20, 36) and mainly carried out in inpatient units (4, 7, 10, 13) or only taking into account one specific substance (12).

It is possible that a large number of results from studies on comorbidity in SUD could be attributed to the characteristics of the personality pathologies, themselves (37). However, it has also been postulated that some interactions between drugs, like alcohol and nicotine (38) or psychoactive substances used simultaneously, like cocaine and alcohol (39), could explain a certain degree of comorbidity.

The general trend in clinical practice seems to identify anxiety and depression mainly in Cluster B patients and vice versa because they seem to present themselves and their symptoms in a more “visible” way. Based on the results of this study it seems to be advisable to identify Cluster C patients in the Addiction Treatment Centers and take into account the fact that this population has high rates of anxiety and depression symptoms.

It is worth noting that patients with Cluster C disorders present maladjustment traits often characterized by high levels of anxiety. Based on the theory of self-medication, SUD could have developed or have been maintained in order to mitigate the consequences of these personality traits. Thus, dealing with these traits and symptoms could be of great interest. Moreover, chronic substance dependence can lead to affective dysregulation, which can contribute to the personality pathology (40). There are new evidence regarding changes in neurobiology and behavior following intermittent ethanol consumption, leading to increase in social anxiety, altered synapses, and reduced neurogenesis, cholinergic, and serotonergic neurons (41).

In Cluster C, PD the most commonly substances for consulting are benzodiazepines. These findings could be explained by the anxiolytic effect of these drugs. On the other hand, patients with PD from this cluster frequently show alcohol dependence (74%). These results support the observed tendency in patients from this group of disorders toward greater alcohol consumption as well as abuse of both stimulants and depressants, which coincides with previous studies (19, 20, 42–45). The prevalence of dependence in legal drugs (alcohol and benzodiazepines) is similar to the other PD group. In contrast, the prevalence of dependence to illegal drugs (opiates, cocaine, and cannabis) is similar to the patients without a PD. It could be hypothesized that they are avoiding the illegal circuits because of obsessive and avoiding cognitions/behaviors and the high levels of stress.

Regardless of the main substance of abuse, poly-consumption is the norm in all patients, though to a lesser extent for those with Avoidant PD. This fact highlights a disturbing situation in which it is necessary to clarify the implications of each substance and their interaction when inside the body. Poly-consumption is an extremely risky practice and requires the assessment of each individual’s particular circumstances to design an appropriate intervention program for that individual’s needs.

The prevalence of men in Cluster C PD is higher, except in the Dependent group, and as opposed to other disorders, there is no correlation between anxiety and depression.

Psychological functioning related to depression and anxiety is characteristic of Cluster C. In fact, the data in this study confirm that patients from Cluster C score higher than other patients (both Without PD and Cluster A and B groups) in depression and state anxiety. However, in their trait anxiety, there are no differences with other PD patients, though they do score higher than patients Without PD. Specifically, within Cluster C, Obsessive–Compulsive PD patients present fewer depressive symptoms and less anxiety (trait and state) than Avoidant and Dependent PD. Therefore, the results on anxiety and depression do not show just one pattern for all the patients with SUD-PD. It is worth highlighting that, as observed in previous studies (46, 47), patients with Cluster C PD are most commonly affected by depression; however, they are not the group with greatest trait anxiety.

Nevertheless, it cannot be ignored that among patients with mood disorders or anxiety, Obsessive–Compulsive, and Avoidant disorders from Cluster C are the most frequent and have the worst prognosis (48, 49). Moreover, the close relation between anxiety and depression for all the groups except for the Dependent PD group clearly shows the complexity of the relation and suggests that in many patients intervention should focus on aspects like depression and anxiety more than on the substance being consumed.

Furthermore, it is important to underline the singularity of the Dependent PD group. For these patients, the negative relation between depression and treatment indicators and positive relation between anxiety and treatment indicators clearly shows that this group within Cluster C should be treated as a distinct group with specific features that need to be considered at treatment level.

This is the first description of the relationship between Cluster C PD and SUD in a clinically large sample. One of the strong points of this study is the use of a systematic evaluation process using semi-structured interviews that provide high diagnostic reliability. As we noted before, the size of most samples studied about these topic have been smaller in comparison to the number of participants included in this research.

The results of the present study should be interpreted in light of the following limitations. The results are limited to patients with PD seeking treatment in a drug unit. It would be very interesting to confirm if SUD patients treated in residential centers show the same prevalence of Cluster C PD; if depression and anxiety are also differential psychological indicators within this Cluster; and if there is the same relation with treatment indicators in a residential center. On the other hand, it seems of interest studying other possible variables such as other comorbidities, the age of onset, family history, and so on.

Finally, it is necessary to analyze the possible implications of basic temperamental traits both in the description of SUD—Cluster C patients as well as in the differential treatment of their addiction.

Reciprocal relationship between substance use, mood, and anxiety disorders has been found (49–51). Given the prevalence of Cluster C disorders in addicts, their systematic assessment should be implemented for all patients seeking treatment. The presence of depression symptoms and anxiety traits can be useful.
to detect the most serious patients and with whom a specific approach should be adopted, especially in Dependent PD.

**AUTHOR CONTRIBUTIONS**

Every author contributed in study design and manuscript preparation, literature review, data collection and analysis, and has approved the final manuscript.

**ACKNOWLEDGMENTS**

The authors would like to thank the support of Grant of the Subdirecció General de Drogodependències (Department of Health. Generalitat de Catalunya) for the study of cocaine dependence and a grant from the Instituto Carlos III: FIS P113/111 “Alucinaciones cenestésicas: factor pronóstico dependiente de cocaína” and a grant from the Delegación del Gobierno para el Plan Nacional sobre Drogas 2013/044: “Complicaciones clínicas y accidentabilidad asociadas a la presencia de síntomas psicóticos en consumidores de cocaína.” These funding sources had not played any role in this research. The authors are also grateful to our research team for their support, particularly Dr. Joan Alvarós, Dr. Angel Egidio, Dr. Abderramán Esojo, Dr. María Robles, Dr. Felipe Palma, Dr. Elena Ros-Cucurull (Psychiatrists), Nina Vela, Alejandra Herrero, Marta Sorribes, and Marta Perea (Psychologists).

**REFERENCES**

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR.* 4th ed. Washington, DC: American Psychiatric Association (2000). text rev.
2. Verheul R. Co-morbidity of personality disorders in individuals with substance use disorders. *Eur Psychiatry* (2001) 16:274–82. doi:10.1016/S0924-9338(01)00578-8
3. Lev-Ran S, Imtiaz S, Rehm J, Le Foll B. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). *Am J Addict* (2013) 22:93–8. doi:10.1111/j.1521-0391.2013.00304.x
4. Grau-López L, Daigre C, Grau-López L, Rodríguez-Cintas L, Egido Á, Casas M, et al. Administrative prevalence of insomnia and associated clinical features in patients with addiction during active substance use. *Actas Esp Psiquiatr* (2016) 44(2):64–71.
5. Comín M, Redondo S, Daigre C, Grau-López L, Casas M, Roncero C. Clinical differences between cocaine-dependent patients with and without antisocial personality disorder. *Psychiatry Res* (2016) 246:587–92. doi:10.1016/j.psychres.2016.10.083
6. Roncero C, Daigre C, Barral C, Ros-Cucurull E, Grau-López L, Rodríguez-Cintas L, et al. Neuroticism associated with cocaine-induced psychosis in cocaine-dependent patients: a cross-sectional observational study. *PLoS One* (2014) 9:e106111. doi:10.1371/journal.pone.0106111
7. Thomas VH, Melchert TP, Banken JA. Substance dependence and personality disorders: comorbidity and treatment outcome in an inpatient treatment population. *J Stud Alcohol* (1999) 60:271–7. doi:10.15288/jsa. 1999.60.271
8. Langás A-M, Malt UF, Opjordsmoen S. In-depth study of personality disorders in first-admission patients with substance use disorders. *BMC Psychiatry* (2012) 12:180. doi:10.1186/1471-244X-12-180
9. Pérez PJÉ, Puerta García C, Lagoes Robas A, Sáez Maldonado A. Prevalencia e intensidad de trastornos de personalidad en adictos a sustancias en tratamiento en un centro de atención a las drogodependencias. *Trast Adict* (2003) 5:241–55. doi:10.1051/s1575-0973(03)70117-2
10. Skinstad AH, Svain A. Comorbidity in a clinical sample of substance abusers. *Am J Drug Alcohol Abuse* (2001) 27:45–64. doi:10.1080/01740730109571
11. Kokkevi A, Stefanis N, Anastasopoulou E, Kostogianni C. Personality disorder in drug abusers: prevalence and their association with AXIS I disorders as predictors of treatment retention. *Addict Behav* (1998) 23:841–53. doi:10.1016/S0306-4603(98)00071-9
12. López Durán A, Becoña Iglesias E. [Patterns and personality disorders in persons with cocaine dependence in treatment]. *Psicothema* (2006) 18: 578–83.
13. Vergara-Moragues E, González-Saiz F, Lozano OM, Verdejo García A. Psycho-pathological stability of personality disorders in substance abuse patients treated in a therapeutic community. *J Addict Dis* (2013) 32:343–53. doi:10.1080/10508873.2013.854154

14. Becker DF, Añez LM, Paris M, Bedregal L, Grilo CM. Factor structure and diagnostic efficiency of the diagnostic and statistical manual of mental disorders, fourth edition, criteria for avoidant personality disorder in Hispanic men and women with substance use disorders. *Compr Psychiatry* (2009) 50:463–7. doi:10.1016/j.comppsych.2008.10.002
15. Fonseca-Pedrero E, Paino M, Lemos-Giráldez S, Muñiz J. Cluster C maladaptive personality traits in a general population of adolescents. *Actas Esp Psiquiatr* (2013) 41(2):97–105.
16. Blecha L, Benyamina A, Reynaud M. [Family management of cannabis in adolescents]. *Arch Pediatr* (2010) 17(2):191–4. doi:10.1016/j.arcped.2009.09.018
17. Arendt M, Rosenberg R, Fjordback L, Brandholdt J, Foldager L, Sher L, et al. Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. *Psychol Med* (2007) 37:935–45. doi:10.1017/ S0033291706009688
18. Khantianz Ef. The self-medication hypothesis of substance use disorders. A reconsideration and recent applications. *Harv Rev Psychiatry* (1997) 4(5):231–44. doi:10.1097/00001622-199705000-00050
19. Benito A, Haro G, Orenzo T, González M, Fornés T, Mateu C. [Opiate dependence type II or antisocial: Cloninger's psychobiological model and its usefulness in addictions]. *Adicciones* (2012) 24:131–8. doi:10.20882/adicciones.106
20. Lorea I, Fernández-Montalvo J, López-Gotii JJ, Landa N. [Cocaine addiction and personality disorders: a study with the MCM-II]. *Adicciones* (2009) 21:57–63. doi:10.20882/adicciones.252
21. Moreno-López L, Albein-Urios N, Martínez-González JM, Soriano-Mas C, Verdejo-García A. Prefrontal gray matter and motivation for treatment in cocaine-dependent individuals with and without personality disorders. *Front Psychiatry* (2014) 5:52. doi:10.3389/fpsyg.2014.00052
22. Van Horn DH, Frank AF. Substance-use situations and abstinence predictions in substance users with and without personality disorders. *Am J Drug Alcohol Abuse* (1998) 24:395–404. doi:10.3109/009529988089016905
23. Nace EP, Davis CW, Gaspari JP. Axis II comorbidity in substance abusers. *Am J Psychiatry* (1991) 148:118–20. doi:10.1176/ajp.148.1.118
24. Agrawal A, Narayanan G, Oltmanns TF. Personality pathology and alcohol dependence at midlife in a community sample. *Personal Disorder* (2013) 4(1):55–61. doi:10.3109/0033291706009688
25. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janini L. Anhedonia and substance dependence: clinical correlates and treatment options. *Front Psychiatry* (2011) 2:10. doi:10.3389/fpsyg.2011.00010
26. Kranzler HR, Satel S, Apter A. Personality disorders and associated features in cocaine-dependent inpatients. *Compr Psychiatry* (1994) 35:335–40. doi:10.1016/0010-440X(94)90272-0
27. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).* Clinician Version. Administration Booklet. New York: American Psychiatric Publishing (2012)
28. First MB. *User's Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders: SCID-II.* New York: American Psychiatric Publishing (1997).
29. Barral C, Rodríguez-Cintas L, Martínez-Luna N, Bachiller D, Perez-Pazos J, Alvarós J, et al. Reliability of the Beck depression inventory in opiate dependent patients. *J Subst Use* (2016) 21(2):128–32. doi:10.3109/14659891.2014.980859
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry (1961) 4:561–71. doi:10.1001/ archpsyc.1961.01710120033010

31. Spielberger CD, Gorsuch RL, Lushene RE. The State-Trait Anxiety Inventory: Preliminary Test Manual for Form X. Tallahassee: Florida State University (1970). [Spanish adaptation, Cuestionario de Ansiedad Estado-Rasgo. Manual, 1986, Madrid: Tea Ediciones].

32. Barnes LLB, Harp D, Jung WS. Reliability generalization of scores on the Spielberger State-Trait Anxiety Inventory. Educ Psychol Mess (2002) 62:603–18. doi:10.1177/0013164402062004005

33. Hishinuma ES, Miyamoto RH, Nishimura ST, Nahulu LB, Andrade NN, Barnes LLB, Harp D, Jung WS. Reliability generalization of scores on the Spielberger State-Trait Anxiety Inventory with older adult psychiatric outpatients. J Anxiety Disorder (1997) 11:33–47. doi:10.1016/S0887-6185(96)00033-3

34. Kabacoff RI, Segal DL, Hersen M, Van Hasselt VB. Psychometric properties of the Spielberger State-Trait Anxiety Inventory. J Pers Assess (2000) 7:17–36. doi:10.1177/1077319900070102

35. Vautier S. A longitudinal SEM approach to STAI data: two comprehensive multitrait-multistate models. J Pers Assess (2004) 83:167–79. doi:10.1207/s15327752jpa8302_11

36. Lysaker PH, Olesek K, Buck K, Leonhardt BL, Vohs J, Ringer J, et al. Metacognitive mastery moderates the relationship of alexithymia with cluster C personality disorders in adults with substance use disorders. Addict Behav (2014) 39(3):558–61. doi:10.1016/j.addbeh.2013.11.007

37. Jahng S, Trull TJ, Wood PK, Tragesser SL, Tomko R, Grant JD, et al. Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity. J Abnorm Psychol (2011) 120:656–69. doi:10.1037/a0023539

38. Funk D, Marinelli PW, Lé AD. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res Health (2006) 29:186–92.

39. McCance EF, Price LH, Kosten TR, Jatlow PI. Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther (1995) 274:215–21

40. Sher KJ, Grekin ER. Alcohol and affect regulation. In: Gross JJ, editor. Handbook of Emotion Regulation. New York: Guilford Press (2007). p. 560–80.

41. Crews FT, Vetrano RP, Broadwater MA, Robinson DL. Adolescent alcohol exposure persistently impacts adult neurobioloy and behavior. Pharmacol Rev (2016) 68(4):1074–109. doi:10.1124/pr.115.12138

42. Dejong CA, van den Brink W, Harreveld FM, van der Wielen EG. Personality disorders in alcoholics and drug addicts. Compr Psychiatry (1993) 34:87–94. doi:10.1016/1096-0890(93)90052-6

43. Echeburúa E, de Medina RB, Aizpiri J. Alcoholism and personality disorders: an exploratory study. Alcohol Alcohol (2005) 40:323–6. doi:10.1093/alcalc/agh158

44. Harrison ER, Haaga J, Richards T. Self-reported drug use data: what do they reveal? Am J Drug Alcohol Abuse (1993) 19:423–41. doi:10.3109/00948339309001632

45. Preuss UW, Johann M, Fehr C, Koller G, Wodarz N, Hesselbrock V, et al. Personality disorders in alcohol-dependent individuals: relationship with alcohol dependence severity. Eur Addict Res (2009) 15:188–95. doi:10.1159/000228929

46. Hardy GE, Barkham M, Shapiro DA, Stiles WB, Rees A, Reynolds S. Impact of Cluster C personality disorders on outcomes of contrasting brief psychotherapies for depression. J Consult Clin Psychol (1995) 63:997–1004. doi:10.1037/0022-006X.63.6.997

47. Morse JQ, Pilkonis PA, Houck PR, Frank E, Reynolds CE. Impact of cluster C personality disorders on outcomes of acute and maintenance treatment in late-life depression. Am J Geriatr Psychiatry (2005) 13:808–14. doi:10.1097/00111565-200509000-00010

48. Grant BF, Hasin DS, Stinson FS, Dawson DA, Chou SP, Ruan WJ, et al. Prevalence, correlates, and disability of personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry (2004) 65:948–58. doi:10.4088/JCP.v65n0711

49. Grant BF, Hasin DS, Stinson FS, Dawson DA, Patricia Chou S, June Ruan W, et al. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. J Psychiatr Res (2005) 39:1–9. doi:10.1016/j.jpsychires.2004.05.004

50. Grant BF, Goldstein RB, Chou SP, Huang B, Stinson FS, Dawson DA, et al. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on alcohol and related conditions. Mol Psychiatry (2009) 14:1051–66. doi:10.1038/mp.2008.41

51. Dimaggio G, D’Urzo M, Passinetti M, Salvatore G, Lysaker PH, Catania D, et al. Metacognitive interpersonal therapy for co-occurrent avoidant personality disorder and substance abuse. J Clin Psychol (2015) 71(2):157–66. doi:10.1002/jcla.22151

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Roncero, de Miguel, Fumero, Abad, Martin, Bethencourt, Grau-López, Rodriguez-Cintas and Daigre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.